Protecting the initial site of viral entry: An alternative HIV vaccine target

Expert Review of Vaccines

Volumn 10, Issue 9, 2011, Pages 1253-1256

  Lopalco, Lucia ^a   Bomsel, Morgane ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INSTITUT COCHIN   (France)

Author keywords

CCR5; gp41; HIV; mucosal antibodies; vaccine

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ENTRY; VIRUS TRANSMISSION;

ADAPTIVE IMMUNITY; AIDS VACCINES; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; AUTOANTIBODIES; FEMALE; GENITALIA, FEMALE; HIV; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; MUCOUS MEMBRANE; RECEPTORS, CCR5; TRANSCYTOSIS; VACCINATION; VIRUS INTERNALIZATION;

EID: 80053035754     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.98     Document Type: Review

References (20)

1. Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu. Rev. Med. 61, 153-167 (2010).
2. McElrath MJ. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J. Infect. Dis. 202(Suppl. 2), S323-S326 (2010).
3. Watkins JD, Siddappa NB, Lakhashe SK et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE 6(3), e18207 (2011).
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
5. Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34(2), 269-280 (2011).
6. Ferrari G, Pollara J, Kozink D et al. A HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 Conformational epitope mediates potent ADCC activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 85(14), 7029-7036 (2011).
7. Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood 104(7), 2205-2206 (2004). (Pubitemid 39297883)
8. Devito C, Broliden K, Kaul R et al. Mucosal and plasma IgA from HIV-1- exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165(9), 5170-5176 (2000).
9. Tudor D, Derrien M, Diomede L et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgGseronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2(5), 412-426 (2009).
10. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006). (Pubitemid 43361590)
11. Donadoni C, Bisighini C, Scotti L et al. Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts. PLoS ONE 5(3), e9920 (2010).
12. Coutant J, Yu H, Clément MJ et al. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J. 22(12), 4338-4351 (2008).
13. Visciano ML, Diomede L, Tagliamonte M et al. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine 29(31), 4903-4912 (2011).
14. Clerici M, Barassi C, Devito C et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the a-helix of gp41. AIDS 16(13), 1731-1741 (2002).
15. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22(3), 358-366 (2010).
16. Barouch DH, OBrien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16(3), 319-323 (2010).
17. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6(1), 20-28 (2009).
18. Lindqvist M, Persson J, Thrn K, Harandi AM. The mucosal adjuvant effect of a-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182(10), 6435-6443 (2009).
19. Lopalco L. CCR5: from natural resistance to a new anti-HIV strategy. Viruses 2, 574-600 (2010).
20. Lopalco L. Natural anti-CCR5 antibodies in HIV-infection and -exposure. J. Transl. Med. 9(Suppl. 1), S4 (2010).